Disease · MONDO_0004608
Comparisons in its trials29
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 29
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| IMRT + Cisplatin vs IMRT + Cetuximab: deaths from any cause | 64 of 406 | 86 of 399 | 805 | NCT01302834 | Trial comparisons |
| IMRT + Cisplatin vs IMRT + Cetuximab: serious adverse events | 177 of 398 | 115 of 394 | 792 | NCT01302834 | Trial comparisons |
| IMRT 6 Weeks + Cisplatin vs IMRT 5 Weeks: deaths from any cause | 6 of 152 | 6 of 147 | 299 | NCT02254278 | Trial comparisons |
| IMRT 6 Weeks + Cisplatin vs IMRT 5 Weeks: serious adverse events | 31 of 152 | 11 of 147 | 299 | NCT02254278 | Trial comparisons |
| Cohort A (Intermediate Risk) vs Cohort B (Extranodal Extension): deaths from any cause | 0 of 38 | 1 of 43 | 81 | NCT01932697 | Trial comparisons |
| Cohort A (Intermediate Risk) vs Cohort B (Extranodal Extension): serious adverse events | 5 of 38 | 5 of 43 | 81 | NCT01932697 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 30 of 30 | 26 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious Grade ≥3 Adverse Events Considered Related to Study Treatment of M7824 | 6 of 30 | 4 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: deaths from any cause | 18 of 30 | 22 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: serious adverse events | 19 of 30 | 21 of 26 | 56 | NCT03427411 | Trial comparisons |
Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 47 of 47 | 3 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: deaths from any cause | 28 of 47 | 0 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: serious adverse events | 18 of 47 | 1 of 3 | 50 | NCT04287868 | Trial comparisons |
| Radiotherapy vs Radiotherapy, Cisplatin: Rate of Distant Metastasis | 2 of 27 | 0 of 11 | 38 | NCT01687413 | Trial comparisons |
| Radiotherapy vs Radiotherapy, Cisplatin: Locoregional Control | 26 of 27 | 9 of 11 | 38 | NCT01687413 | Trial comparisons |
| Radiotherapy vs Radiotherapy, Cisplatin: deaths from any cause | 1 of 27 | 0 of 11 | 38 | NCT01687413 | Trial comparisons |
| Radiotherapy vs Radiotherapy, Cisplatin: serious adverse events | 0 of 27 | 1 of 11 | 38 | NCT01687413 | Trial comparisons |
| Radiotherapy vs Radiotherapy, Cisplatin: Number of Participants With Disease-free Survival (DFS) | 24 of 24 | 10 of 11 | 35 | NCT01687413 | Trial comparisons |
| Radiotherapy vs Radiotherapy, Cisplatin: Disease Specific Survival | 24 of 24 | 10 of 10 | 34 | NCT01687413 | Trial comparisons |
| Cervical vs NonCervical: Number of Patients With Serious and Non-serious Adverse Events | 18 of 18 | 11 of 11 | 29 | NCT01585428 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004608/comparisons